Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Flu cases skyrocket in US. See cases, where people got sick. - 2Amid growing bipartisan scrutiny of Pete Hegseth, Trump says he 'wouldn't have wanted … a second strike' on alleged Venezuelan drug boat survivors
- 3Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
- 4Intriguing Strange Cruising Objections you Should Visit
- 5Nature's Treats: 10 Organic products That Lift Prosperity
- NASA's moon mission has begun — here's what's ahead for the Artemis II astronauts
- The largest sun of 2026 rises today as Earth draws closest to our parent star
- Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes
- Iranian rockets hit Tel Aviv area, injuring six
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- ByHeart sued over recalled formula by parents of infants sickened with botulism
- Find Your Internal Culinary expert: Cooking Strategies and Recipes
- California warns of death cap mushrooms outbreak resulting in 3 deaths
- Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
